Although preclinical studies in rodent models have provided extensive insights into the anti-obesity mechanisms of plant-derived polysaccharides, including effects on lipid metabolism, insulin sensitivity, and gut microbiota modulation, translational validation in human populations remains essential for evaluating their clinical potential. This evidence concerns the gene INS and obesity disorder.